Want to take quizzes and track your credits?
What are the outcomes associated with the use of imatinib in the treatment of metastatic or locally advanced dermatofibrosarcoma protuberans (DFSP)?
This systematic review finds that imatinib is associated with a complete or partial DFSP response in more than 60% of advanced cases, regardless of 400-mg or 800-mg daily dose. Severe adverse events occurred in about 15% of all cases.
Imatinib should be considered a safe and effective therapy for advanced DFSP at a 400-mg/d starting dose.
Dermatofibrosarcoma protuberans (DFSP) has the potential for local destruction and recurrence, although it carries a low risk of metastasis. Complete surgical resection with negative margins is considered the gold standard for treatment; however, there are cases that are unresectable owing to tumor extension or size or owing to risk of cosmetic and/or functional impairment. Imatinib treatment has been used for locally advanced or metastatic DFSP.
To evaluate the usefulness of imatinib for treating DFSP.
We conducted a systematic review on the PubMed and Embase databases for articles published from September 2002 through October 2017 using the key words “dermatofibrosarcoma” or “dermatofibrosarcoma protuberans” AND “therapy” AND “imatinib.” References within retrieved articles were also reviewed to identify additional studies. Studies of adults with histologically proven DFSP treated with imatinib as monotherapy or as an adjuvant or neoadjuvant therapy to surgery were included. Extracted data were analyzed using descriptive statistics. PRISMA guidelines were followed. All analysis took place October through December 2017.
Nine studies met inclusion criteria; 152 patients were included. The calculated mean patient age was 49.3 years (range, 20-73 years). Calculated mean tumor diameter was 9.9 cm (range, 1.2-49.0 cm). When COL1A1-PDGFβ protein translocation (collagen, type 1, alpha 1–platelet-derived growth factor β) was reported, it was present in 90.9% of patients (111 of 122). Complete response was seen in 5.2% of patients (8 of 152), partial response in 55.2% (84 of 152), stable disease in 27.6% (42 of 152), and progression in 9.2% (14 of 152). Four of the 152 patients (2.6%) were excluded from the analysis owing to unknown or unevaluable response. There were no differences in response rate using 400-mg or 800-mg daily doses (67.5% or 27 of 40 patients for 400-mg dose vs 67.1% or 49 of 73 patients for 800-mg dose complete or partial response; P > .99). Adverse events were present in at least 73.5% of cases (78 of 106); severe adverse events were present in 15.1% of cases (20 of 132).
Conclusions and Relevance
Imatinib is a useful directed therapy in patients with DFSP who are not surgical candidates owing to disease extension or significant cosmetic or functional impairment. There seems to be no difference between 400- or 800-mg daily doses.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Accepted for Publication: November 4, 2018.
Corresponding Author: Kishwer S. Nehal, MD, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 16 E 60th St, New York, NY 10022 (email@example.com).
Published Online: January 2, 2019. doi:10.1001/jamadermatol.2018.4940
Author Contributions: Drs Navarrete-Dechent and Nehal had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Navarrete-Dechent, Barker, Nehal.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Navarrete-Dechent, Mori, Dickson, Nehal.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Navarrete-Dechent.
Obtained funding: Navarrete-Dechent, Nehal.
Administrative, technical, or material support: Navarrete-Dechent, Mori, Nehal.
Supervision: Navarrete-Dechent, Barker, Nehal.
Conflict of Interest Disclosures: None reported.
Funding/Support: This research was funded in part by a grant from the National Cancer Institute/National Institutes of Health (P30-CA008748) made to the Memorial Sloan Kettering Cancer Center.
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
You currently have no searches saved.